Type | Sym | Class | Transaction | Value $ | Shares | Change % | Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
holding | IMNM | Common Stock | 19.9K | Oct 2, 2023 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | IMNM | Stock Option (Right to Buy) | Oct 2, 2023 | Common Stock | 39.7K | $1.35 | Direct | F2 | ||||||
holding | IMNM | Stock Option (Right to Buy) | Oct 2, 2023 | Common Stock | 134K | $1.06 | Direct | F2 |
Id | Content |
---|---|
F1 | Mr. Rosett was appointed as SVP Operations of the Issuer effective immediately after the Effective Time (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by and among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.). In connection with the Closing (as defined in the Merger Agreement) and prior to Mr. Rosett being appointed an executive officer of the Issuer, Mr. Rosett exchanged (i) his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer and (ii) his shares of common stock of Morphimmune for shares of the Issuer. |
F2 | 25% of the shares vested on March 24, 2023, and the remaining shares shall vest in 36 monthly installments thereafter. |
See Attached Exhibit 24